Scientists Identify New Type of Dementia That Mimics Alzheimer’s

Some people who have been diagnosed with Alzheimer’s may actually have a newly defined type of dementia that mimics the disease’s symptoms but is caused by another mechanism in the brain. And while that doesn’t change the search for a cure for Alzheimer’s or the newly classified type of dementia, distinguishing between the two is essential for meaningful research that could narrow down a cause, according to scientists.

Dementia is an umbrella term used to refer to many types of neurodegenerative diseases—one of which is Alzheimer’s. And while the majority of dementias are diagnosed as Alzheimer’s, a recent study showed that thousands of people diagnosed with Alzheimer’s actually didn’t have the disease.

“Late research and clinical preliminaries in Alzheimer’s sickness have shown us two things: First, not the majority of the general population we thought had Alzheimer’s have it; second, it is essential to comprehend different supporters of dementia,” said Nina Silverberg, Ph.D., executive of the Alzheimer’s Disease Centers Program at the National Institute on Aging.

“We proposed another name to expand acknowledgment and research for this regular reason for dementia, the manifestations of which mirror Alzheimer’s dementia yet isn’t brought about by plaques and tangles (the development of beta-amyloid proteins that Alzheimer’s produces). Or maybe, LATE dementia is brought about by stores of a protein called TDP-43 in the cerebrum,” said Dr. Julie Schneider, M.D., senior creator of the Brain paper and partner executive of the Rush Alzheimer’s Disease Center.

“In excess of 200 diverse infections can cause the regular cold,” said Dr. Diminish Nelson of the Sanders-Brown Center on Aging at the University of Kentucky, “So for what reason would we think there is only one reason for dementia?”

“LATE most likely reacts to unexpected medicines in comparison to AD, which may help clarify why such a significant number of past Alzheimer’s medications have flopped in clinical preliminaries,” he said. “Since mainstream researchers are in agreement about LATE, further investigation into the ‘how’ and ‘why’ can enable us to create ailment explicit medications that objective the correct patients.”